NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting experience.
Prior to joining Melt Pharmaceuticals, Osborne worked for 10 years with Precigen, Inc. (formerly Intrexon Corporation), a Nasdaq-listed discovery and clinical-stage biopharmaceutical company, having served the last five years as Vice President, Finance and Accounting. During his tenure with Precigen, he managed all finance and accounting activities related to Precigen’s initial public offering, multiple private and public equity and debt capital raises, SEC reporting and compliance, mergers and acquisitions, divestitures, and budgeting. Prior to joining Precigen, Osborne served as Accounting Director, Portfolio Investments, for Third Security, LLC, a manager of a portfolio of biotechnology companies, where he advised its companies on various accounting and finance matters. Osborne began his career with public accounting firm KPMG LLP and held a number of audit practice positions of increasing responsibility, advancing to Audit Senior Manager. He has a B.S. in Accounting from Virginia Tech and is a certified public accountant.
“We are very fortunate to add to our management team an industry veteran with Brad’s financial and business acumen,” said Dr. Larry Dillaha, CEO of Melt Pharmaceuticals. “His industry experience in financial management and accounting, including strategic planning, budgeting and resource allocation, combined with his successful track record in leadership and management, will be instrumental in helping to guide our company through our ongoing Phase 2 pivotal efficacy study for MELT-300 and our overall development and commercial strategy for our patented MELT technology. In addition, Brad brings a wide range of expertise in private and public company offerings, IPOs, M&A, and corporate planning and governance, which should be invaluable as we grow the Company in years to come. We welcome Brad to the executive leadership team and look forward to his contributions.”
About Melt Pharmaceuticals
Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of patented non-intravenous and non-opioid sedation and analgesia medicines for short-duration medical procedures in outpatient and in-office settings. Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States. Melt Pharmaceuticals, Inc. was carved out of Harrow Health, Inc. (Nasdaq: HROW) in 2019. To learn more about Melt, please visit their website, www.meltpharma.com.